Hierarchical models for probabilistic dose-response assessment.

Probabilistic risk assessment is gaining acceptance as the most appropriate way to characterize and communicate uncertainties in estimates of human health risk and/or reference levels of exposure such as benchmark doses. Although probabilistic techniques are well established in the exposure-assessment component of the National Research Council's risk-assessment paradigm, they are less well developed in the dose-response-assessment component. This paper proposes the use of hierarchical statistical models as tools for implementing probabilistic dose-response assessments, in that such models provide a natural connection between the pharmacokinetic (PK) and pharmacodynamic (PD) components of dose-response models. The results show that incorporating internal dose information into dose-response assessments via the coupling of PK and PD models in a hierarchical structure can reduce the uncertainty in the dose-response assessment of risk. However, information on the mean of the internal dose distribution is sufficient; having information on the variance of internal dose does not affect the uncertainty in the resulting estimates of excess risks or benchmark doses. In addition, the complexity of a PK model of internal dose does not affect how the variability in risk is measured via the ultimate endpoint.

[1]  Bradley P. Carlin,et al.  BAYES AND EMPIRICAL BAYES METHODS FOR DATA ANALYSIS , 1996, Stat. Comput..

[2]  Harvey J Clewell,et al.  Evaluation of Physiologically Based Pharmacokinetic Models in Risk Assessment: An Example with Perchloroethylene , 2005, Critical reviews in toxicology.

[3]  P. Watanabe,et al.  Resolution of dose-response toxicity data for chemicals requiring metabolic activation: example--vinyl chloride. , 1978, Toxicology and applied pharmacology.

[4]  T. Starr,et al.  Quantitative cancer risk estimation for formaldehyde. , 1990, Risk analysis : an official publication of the Society for Risk Analysis.

[5]  C Eric Hack,et al.  Bayesian analysis of physiologically based toxicokinetic and toxicodynamic models. , 2006, Toxicology.

[6]  Paul M Schlosser,et al.  Benchmark dose risk assessment for formaldehyde using airflow modeling and a single-compartment, DNA-protein cross-link dosimetry model to estimate human equivalent doses. , 2003, Risk analysis : an official publication of the Society for Risk Analysis.

[7]  J Van Ryzin,et al.  A dose-response model incorporating nonlinear kinetics. , 1987, Biometrics.

[8]  D. Gaylor,et al.  A mechanistic approach to modelling the risk of liver tumours in mice exposed to fumonisin B1 in the diet , 2001, Food additives and contaminants.

[9]  Melvin E. Andersen,et al.  Applying Mode-of-Action and Pharmacokinetic Considerations in Contemporary Cancer Risk Assessments: An Example with Trichloroethylene , 2004 .

[10]  Division on Earth Risk Assessment in the Federal Government: Managing the Process , 1983 .

[11]  M E Andersen,et al.  Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. , 1995, Toxicology letters.

[12]  A. Gelman,et al.  Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions , 1996 .

[13]  D. Krewski,et al.  Toxicological Risk Assessment , 2019 .

[14]  R L Kodell,et al.  Upper confidence limits on excess risk for quantitative responses. , 1993, Risk analysis : an official publication of the Society for Risk Analysis.

[15]  David B. Dunson,et al.  Improving Risk Assessment: Research Opportunities in Dose Response Modeling to Improve Risk Assessment , 2002 .

[16]  Tony Cox,et al.  The Impact of Cytochrome P450 2E1‐Dependent Metabolic Variance on a Risk‐Relevant Pharmacokinetic Outcome in Humans , 2003, Risk analysis : an official publication of the Society for Risk Analysis.

[17]  Hugh A Barton,et al.  Framework for Evaluation of Physiologically‐Based Pharmacokinetic Models for Use in Safety or Risk Assessment , 2004, Risk analysis : an official publication of the Society for Risk Analysis.

[18]  Ralph L Kodell,et al.  A probabilistic framework for non-cancer risk assessment. , 2007, Regulatory toxicology and pharmacology : RTP.

[19]  John F. Young,et al.  Analysis of Methylmercury Disposition in Humans Utilizing A PBPK Model and Animal Pharmacokinetic Data , 2001, Journal of toxicology and environmental health. Part A.

[20]  Michael F. W. Festing,et al.  Use of a Multistrain Assay Could Improve the NTP Carcinogenesis Bioassay , 1995 .

[21]  F. A. Smith,et al.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.

[22]  Notes on likelihood intervals and profiling , 2000 .